Today FDA released a draft guidance to further clarify how it evaluates interoperable medical devices. As the name of the document states, “Design Considerations and Pre-market Submission Recommendations for Interoperable Medical Devices” intends to offer information related to design of such devices, including security and risk management and verification and validation, along with what should be included in pre-market submissions and device labeling.
“Interoperability refers to the ability of medical devices to interact with other medical devices and systems, including electronic health record systems, and to communicate with each other using a common vocabulary,” according to an agency release. “Connecting interoperable medical devices can improve the efficiency of health care through means such as automatically populating an electronic health record or allowing doctors to monitor their patients remotely to make treatment decisions without physically being in the hospital.”
There is a 60-day comment period for the draft guidance.
Related Articles
-
The MDDT program was developed in collaboration with the National Institutes of Health’s (NIH’s) National Institute of Drug Abuse (NIDA), National Institute of Dental Craniofacial Research (NIDCR) and National Cancer Institute (NCI) as a way for the FDA to qualify…
-
At Device Talks Boston in May, Ronald Kurz, Sr. Director and GM at Canon Virginia, Kathryn Unger, Sr. Mgr. of Global ESG Communications at Boston Scientific, and David Ettl, COO at Gradian Health System, addressed the question, how can we…
-
The Food and Drug Omnibus Reform Act (FDORA) authorized FDA to conduct remote device facility inspections. While it will take time for the FDA to take the necessary steps to start performing remote inspections, industry can look to remote regulatory…
-
Following Karl Storz’s recall of urological endoscopes, the agency wants to make sure that healthcare providers have seen the company’s urgent labeling update involving sterilization methods.
